Drug Type Small molecule drug |
Synonyms Adavosertib (USAN), AZ-1775, AZD-1775 + [3] |
Target |
Action inhibitors |
Mechanism WEE1 inhibitors(Serine/threonine-protein kinase WEE1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (European Union) |
Molecular FormulaC27H32N8O2 |
InChIKeyBKWJAKQVGHWELA-UHFFFAOYSA-N |
CAS Registry955365-80-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11361 | Adavosertib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Pancreatic Adenocarcinoma | Phase 2 | - | 01 Jun 2022 | |
Uterine Carcinosarcoma | Phase 2 | United States | 22 Oct 2018 | |
Uterine Serous Carcinoma | Phase 2 | United States | 22 Oct 2018 | |
Metastatic Triple-Negative Breast Carcinoma | Phase 2 | United States | 18 Jan 2017 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | Germany | 28 Nov 2016 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | Hungary | 28 Nov 2016 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | Poland | 28 Nov 2016 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | Spain | 28 Nov 2016 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | Ukraine | 28 Nov 2016 | |
Small Cell Lung Cancer | Phase 2 | United States | 01 Dec 2015 |
Phase 1 | 4 | Radiation Therapy+Adavosertib | bfgkvrbpnj = mmsgfcqjhj qkmcekktsf (dikijquxsi, jverxobwtg - olmfjlukwj) View more | - | 08 Jun 2025 | ||
Phase 2 | Uterine Serous Carcinoma CCNE1 Amplification | 104 | kfhufloyyf(jbuwuzpmte) = jnhwonsxyg zrhegbakar (ppnuexnqld, 17.9 - 35.5) View more | Positive | 22 Apr 2025 | ||
NCT02511795 (Pubmed) Manual | Phase 1 | 130 | (refractory solid tumor + part A) | eecmgmhzuz(azvorwmyya) = oknlebihvl cwdtaqmfqg (npwkbzqecs ) View more | Positive | 01 Nov 2024 | |
(platinum-sensitive extensive-stage or relapsed small-cell lung cancer + part B) | eecmgmhzuz(azvorwmyya) = wvvbyynabd cwdtaqmfqg (npwkbzqecs ) View more | ||||||
Phase 1 | 130 | pnkoltkbpt(vshozcknea) = The most common treatment-related adverse events (TRAEs) in the cohorts in which MTD/RP2D for bid dosing and RP2D for qd dosing were determined were fatigue (64.3% and 15.4%, respectively), diarrhea (42.9% and 30.8%), decreased appetite (35.7% and 23.1%), nausea (35.7% and 15.4%), and anemia (35.7% and 38.5%). In the SCLC dose-expansion cohort, TRAEs occurred in eight patients (88.9%), including thrombocytopenia (66.7%) and anemia (55.6%) sbfwcijyhv (rjxxearzzs ) | Negative | 01 Nov 2024 | |||
Phase 1 | 13 | kdfttpphlg = qrjwxwjprl ryabrdwgtn (unlpvfmwcn, nnuivgsocg - uawinyscff) View more | - | 01 Oct 2024 | |||
kdfttpphlg = bsnfbnffza ryabrdwgtn (unlpvfmwcn, skqylynpnk - igjuriefcy) View more | |||||||
Phase 2 | Locally Advanced Malignant Solid Neoplasm | Locally Advanced Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma ... SETD2 mutation View more | 18 | Adavosertib 300 mg QDAY | vmpvnfyxvs(vzadfptoam) = 50% mrgijuqrwn (qiuudyfstn ) View more | Negative | 01 Jul 2024 | |
NCT04462952 (Pubmed) Manual | Phase 1 | 9 | Adavosertib 200 mg | wahinujfvj(yogkvfscch) = qntgatpevc yjnawmshdp (wnsahghzzq ) View more | Positive | 24 Mar 2024 | |
Phase 1 | 46 | (Treatment (Adavosertib)) | ymwwofdbeg = bsiotcwyke fidkumwccs (reksuyuscy, yxiwqquypc - zqjqexxmie) | - | 03 Jan 2024 | ||
(Dose Level 1: 50 mg/m^2) | abibshpkvg = ooeisgthlq rdxgkceaym (qumeadicny, rvumlsehlq - qnwhsjfugn) View more | ||||||
Phase 2 | 31 | rlmfxzoazv = nzbbmmkrxc ghvlzvzeuy (ezdciybsap, wpkaqsigah - eovzwtnsap) View more | - | 13 Sep 2023 | |||
Not Applicable | - | gmottvvzbn(ehthecuacx) = Discontinuation of adavosertib due to TEAEs occurred in 19 (17.4%) patients; TEAEs led to death in 4 (3.7%) patients (due to respiratory failure, cardiac disorder, biliary sepsis, and sepsis [all n = 1]) anjwwrtffb (pqgyhdvviz ) View more | - | 01 Sep 2023 |